71-year-old female with history of melanoma. Metastatic melanoma liver lesion. Evaluate post-chemoembolization. ABDOMEN:LIVER, BILIARY TRACT: Innumerable bilobar T2 hyperintense lesions that demonstrate restricted diffusion and are compatible with metastatic disease. Some of these lesions are T1 hyperintense on the precontrast series compatible with the history of melanoma. Index lesion measurements listed below. The hepatic vessels are compressed but patent. These lesions are relatively stable in number compared to to the partially visualized liver on the 10/15/2016 CT chest exam.Since the right hepatic chemoembolization, some right-sided lesions demonstrate no postcontrast enhancement, and others show peripheral enhancement, and some still demonstrate solid enhancement. These findings are likely related to posttreatment effect.SPLEEN: No significant abnormality noted.PANCREAS: No significant abnormality noted.ADRENAL GLANDS: No significant abnormality noted.KIDNEYS, URETERS: Left lower pole renal cyst.RETROPERITONEUM, LYMPH NODES: No significant abnormality noted.BOWEL, MESENTERY: No significant abnormality noted.BONES, SOFT TISSUES: There are T1 hyperintense lesions in the iliac bones and lower lumbar spine that demonstrate contrast enhancement on the subtraction series (series 12 images 7, 12, 15, 23, 27) (series 10012 images 6, 11, 16, 23, 27), compatible with unchanged osseous metastatic disease compared to the 11/29 2016 MRI lumbar and pelvic exams.OTHER: No significant abnormality noted.INDEX LESION MEASUREMENTS (Current exam date/time: 12/20/2016 09:00:00)SEGMENT 7 LESION: 2.1 x 1.7 cm (Image 12, Series 9).
1.Innumerable bilobar hepatic lesions compatible with metastatic disease. Some lesions are apparently T1 hyperintense and compatible with the history of melanoma.2.Since the right hepatic chemoembolization, some right-sided lesions demonstrate no postcontrast enhancement, and others show peripheral enhancement, and some still demonstrate solid enhancement. These findings are likely related to posttreatment effect.3.Unchanged osseous metastatic disease in the pelvis and lower lumbar spine.